(7-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic acid ethyl ester | 108972-18-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: (7-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic acid ethyl ester
• 英文别名: (7-methoxy-1,2,3,4-tetrahydro-napthalen-2-yl)-acetic acid ethyl ester；(7-methoxy-1,2,3,4-tetrahydro-[2]naphthyl)-acetic acid ethyl ester；(7-Methoxy-1,2,3,4-tetrahydro-[2]naphthyl)-essigsaeure-aethylester；ethyl 2-(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetate
• CAS: 108972-18-5
• 化学式: C₁₅H₂₀O₃
• 分子量: 248.322
• InChiKey: ZUFOHCBMWOZZTH-UHFFFAOYSA-N

物化性质

• 沸点：
  140-142 °C(Press: 0.5 Torr)
• 密度：
  1.059±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (7-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic acid ethyl ester 在 氢溴酸 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 4.0h， 以67%的产率得到1,2,3,4-tetrahydro-7-hydroxynaphthalene-2-acetic acid
  参考文献：
  名称：

  5-脂氧合酶抑制剂的设计与合成

  摘要：

  基于对5-脂氧合酶的底物特异性和已知的反应立体化学过程，开发了酶活性位点的假设模型，并用于设计两种类型的5-脂氧合酶的选择性抑制剂。两种抑制剂类型均使用芳族环代替底物的（Z）-烯烃，并被设计为模拟花生四烯酸的非极性末端。一种抑制剂类型与已知的环氧合酶抑制剂类似，使用羧酸与酶的O结合中心相互作用，而另一种抑制剂则采用羟胺功能与预计在酶活性位点的酪氨酸或半胱氨酸自由基相互作用。 。选择性5-脂氧合酶抑制剂是7-（己氧基）萘-2-乙酸（1）和N-甲基；-N（7-丙氧基萘-2-乙基）羟胺（2）。讨论了两种抑制剂的构效关系。

  DOI：

  10.1002/hlca.19880710528
• 作为产物：
  描述：

  7-甲氧基-1-萘满酮 在 palladium on activated charcoal sodium tetrahydroborate 、 氢气 、 4-甲基苯磺酸吡啶 、 sodium hydride 、 碳酸氢钠 、 间氯过氧苯甲酸 、 zinc(II) iodide 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 甲苯 、 苯 为溶剂， 25.0 ℃ 、100.0 kPa 条件下， 反应 13.0h， 生成 (7-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic acid ethyl ester
  参考文献：
  名称：

  New Platelet Fibrinogen Receptor Glycoprotein IIb-IIIa Antagonists:  Orally Active Series of N-Alkylated Amidines with a 6,6-Bicyclic Template

  摘要：

  The design, synthesis, and pharmacological evaluation of (S)-(-)-ethyl [6-[4-(morpholino-formimidoyl)benzamido]-3,4-dihydro-2H-1-benzopyran-3-yl]acetate hydrochloride ((S)-4 . HCl, MS-180), an orally active glycoprotein IIb-IIIa (GPIIb-IIIa) antagonist, are reported. Pharmacophore mapping of amidino and carboxyl groups of already known GPIIb-IIIa antagonists led to the synthesis of nine amidino acids containing 6,6-bicyclic ring skeletons (10a-i). Among them, the compounds 10a,c,e having an amide bond and 1,2,3,4-tetrahydronaphthalene or 3,4-dihydro-2H-1-benzopyran skeleton showed marked inhibitions with IC50 values of 46-57 nM in human platelet aggregation assay in vitro, but low oral activities. N-Alkylation of the amidino group coupled with the ester prodrug approach afforded MS-180 ((S)-4 . HCl), which generates in vivo the corresponding carboxylic acid (S)-3 as an active species. In vitro, (S)-3 inhibited ADP-induced aggregation of guinea pig, dog, and human platelets (IC50 = 110, 253, and 35 nM, respectively) and inhibited the binding of fibrinogen to immobilized GPIIb-IIIa of human platelets (IC50 = 0.12 nM). After oral administration of MS-180 ((S)-4 . HCl) to fasted beagle dog, ex vivo inhibition of platelet aggregation was observed. The maximal inhibitions were observed 2-4 h after dosing with dose dependency (60% inhibition at a dose of 1 mg/kg, 85% at 3 mg/kg, and 100% at 10 mg/kg, respectively) and the extent of the inhibitions paralleled the plasma concentration of the active species (S)-3. On the basis of these studies, we selected MS-180 ((S)-4 . HCl) as a candidate for clinical evaluation as a drug for the treatment and prevention of thrombosis in patients.

  DOI：

  10.1021/jm9801859

文献信息

• Compounds that modulate PPAR activity and methods of preparation
  申请人：——

  公开号：US20030207915A1

  公开（公告）日：2003-11-06

  This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.

  这项发明揭示了能够改变PPAR活性的化合物。该发明还揭示了这些化合物的药用盐、包含这些化合物或其盐的药用组合物，以及将它们用作治疗或预防哺乳动物高脂血症和高胆固醇血症的治疗剂的方法。本发明还揭示了制备所述化合物的方法。
• [EN] RADIOLABELED COMPOUNDS AND METHODS THEREOF<br/>[FR] COMPOSÉS RADIOMARQUÉS ET LEURS PROCÉDÉS
  申请人：GE HEALTHCARE LTD

  公开号：WO2011150183A1

  公开（公告）日：2011-12-01

  The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.

  本发明涉及放射诊断化合物，制备这些化合物的方法，以及将其用作HA血清素5-HT1A受体的成像剂，用于PET或SPECT，更好地使用PET的方法。还披露了包含放射标记化合物的成像有效量的组合物。本发明还涉及非放射标记化合物，制备这些化合物的方法，以及将其用于治疗各种神经学和/或精神疾病的方法。
• Bicyclic antagonists selective for the alphavbeta3 integrin
  申请人：Wyeth

  公开号：US20030109523A1

  公开（公告）日：2003-06-12

  This invention provides novel bicyclic compounds of Formula (I): 1 wherein u, v, m, Y, G, A-B, R 1 , R 1a , R 2 , R 4 , R 5 , R 5a , and R 5b are defined in the specification which compounds exhibit activity as inhibitors of bone resorption and compounds of Formula (II) 2 wherein u, v, m, Y, G, D, A-B, R 1 , R 1a , R 2 , R 3 R 4 , R 5 , R 5a , and R 5b are defined in the specification which compounds exhibit activity as inhibitors of bone resorption.

  这项发明提供了公式（I）的新型双环化合物：其中u、v、m、Y、G、A-B、R1、R1a、R2、R4、R5、R5a和R5b在规范中有定义，这些化合物表现出抑制骨吸收的活性，以及公式（II）的化合物：其中u、v、m、Y、G、D、A-B、R1、R1a、R2、R3、R4、R5、R5a和R5b在规范中有定义，这些化合物也表现出抑制骨吸收的活性。
• RADIOLABELED COMPOUNDS AND METHODS THEREOF
  申请人：Newington Ian Martin

  公开号：US20130064770A1

  公开（公告）日：2013-03-14

  The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.

  本发明涉及放射性诊断化合物、制备这些化合物的方法以及将其用作成像剂的方法，优选地用于PET或SPECT，特别是HA 5-HT1A受体，其中包括成像有效量的放射性标记化合物的组合物。本发明还涉及非放射性标记化合物、制备这些化合物的方法以及将其用于治疗各种神经和/或精神障碍的方法。
• 一种并环类衍生物及其制备方法和医药用途
  申请人：深圳信立泰药业股份有限公司

  公开号：CN115594669A

  公开（公告）日：2023-01-13

  本发明属于化学药物技术领域，涉及式(I)的化合物、其制备方法及其在医药上的应用。具体而言，本发明提供式(I)的化合物或其立体异构体、互变异构体、药学上可接受的盐。这些化合物是胰高血糖样肽‑1受体(GLP‑1R)的激动剂。本发明还涉及包含这些化合物的药物组合物以及使用该化合物治疗糖尿病等疾病的药物中的用途。